First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocri... von Aggarwal, Rahul Raj, Zhang, Jingsong, Monk, Paul, Zhu, Xinhua, Costin, Dan, Petrylak, Daniel P., Borderies, Pascal, Deshpande, Rashmi Majali, Hafeez, Amir, O'Neill, Vincent J., Tagawa, Scott T.

Volltext

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocri... von Aggarwal, Rahul Raj, Zhang, Jingsong, Zhu, Xinhua, Monk, Paul, Jones, Robert J., Linch, Mark David, Costin, Dan, De Bono, Johann S., Karsh, Lawrence Ivan, Petrylak, Daniel P., Borderies, Pascal, Deshpande, Rashmi Majali, Hafeez, Amir, O'Neill, Vincent J., Tagawa, Scott T.

Volltext

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocar... von Zhang, Jingsong, Aggarwal, Rahul Raj, Tagawa, Scott T., Linch, Mark David, Petrylak, Daniel P., Costin, Dan, De Bono, Johann S., Jones, Robert, Karsh, Lawrence Ivan, Zhu, Xinhua, Borderies, Pascal, Deshpande, Rashmi Majali, O'Neill, Vincent, Monk, Paul

Volltext

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-ce... von Tagawa, Scott T., Zhang, Jingsong, Monk, Paul, Zhu, Xinhua, Jones, Robert, Linch, Mark David, Costin, Dan, De Bono, Johann S., Karsh, Lawrence Ivan, Petrylak, Daniel P., Borderies, Pascal, Deshpande, Rashmi Majali, O'Neill, Vincent, Aggarwal, Rahul Raj

Volltext